Abstract
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
Original language | English (US) |
---|---|
Pages (from-to) | 520-531 |
Number of pages | 12 |
Journal | Formulary |
Volume | 30 |
Issue number | 9 |
State | Published - 1995 |
ASJC Scopus subject areas
- Pharmaceutical Science